BOULDER, Colo.--(BUSINESS WIRE)--Apr. 19, 2009-- Array BioPharma Inc. (NASDAQ: ARRY) today announced the presentation of an abstract detailing positive data for its novel, small-molecule p38 / Tie2 inhibitor, ARRY-614. In this study, ARRY-614 demonstrated the potential for potent inhibition of cytokine synthesis, including IL-6 and TNF, and anti-tumor activity in hematological cancers. The data was presented at the American Association for Cancer Research (AACR) 100th Annual Meeting. The complete poster is available as a PDF on Array's website at www.arraybiopharma.com.
